Proclara Biosciences to Present at 28th Annual Piper Jaffray Healthcare Conference

CAMBRIDGE, Mass.--()--Proclara Biosciences, a biotechnology company developing novel therapies for diseases caused by protein misfolding, today announced that Franz Hefti, Ph.D., president and chief executive officer, will present a company overview at the 28th Annual Piper Jaffray Healthcare Conference on Wednesday, November 30, 2016 at 11:50 a.m. ET in New York City.

About Proclara Biosciences

Proclara Biosciences is a biotechnology company advancing product candidates developed based on proprietary GAIM technology, which is capable of simultaneously targeting multiple toxic misfolded proteins. The broad applicability of the Proclara technology enables the company to target multiple protein misfolding diseases, including neurodegenerative diseases and several rare systemic amyloidoses. The lead GAIM drug candidate, NPT088, is in clinical development for the treatment of Alzheimer’s disease. For more information, please visit proclarabio.com.

Contacts

Media:
Ten Bridge Communications
Dan Quinn, 781-475-7974
dan@tenbridgecommunications.com
or
Investor Relations:
Stern Investor Relations, Inc.
Hannah Deresiewicz, 212-362-1200
hannahd@sternir.com

Release Summary

Proclara Biosciences announced that Franz Hefti, Ph.D., president and chief executive officer, will present a company overview at the Piper Jaffray Healthcare Conference on Wednesday, November 30.

Contacts

Media:
Ten Bridge Communications
Dan Quinn, 781-475-7974
dan@tenbridgecommunications.com
or
Investor Relations:
Stern Investor Relations, Inc.
Hannah Deresiewicz, 212-362-1200
hannahd@sternir.com